Mankind Pharma

Price chart

Previous close

₹2,582.90

Open

₹2,599.50

Day high

₹2,705.00

Day low

₹2,585.20

Listed on NSE since 9 May 2023.

Futures and options

Futures, 23 Nov expiry

₹2,631.10

Discount to the share price

−0.70 (−0.03%)

Futures open interest

12,038 contracts (+135 today)

Lot size (NOV 26)

250 shares

Source: NSE, 09-Nov-2026 12:05:08, delayed. Option chain · All futures · Lot sizes

Pivot levels

R3

2,616.33

R2

2,580.67

R1

2,560.33

CPR top

2,532.33

Pivot

2,524.67

CPR bottom

2,517.00

S1

2,504.33

S2

2,468.67

S3

2,448.33

From Friday 6 November’s high, low and close (Yahoo Finance). Arithmetic on past prices, not a forecast.

Market value

₹1,10,457 Cr

P/E (trailing)

49.30

EPS (trailing)

₹54.24

Price to book

6.28

Dividend yield

0.00%

Return on equity

13.6%

Debt to equity

0.30

Profit margin

14.6%

Beta

0.43

Volume today

10.47 L

Average volume

5.49 L

Source: Yahoo Finance. Ratios use the latest reported (trailing twelve-month) figures.

Source: Yahoo Finance, from annual reports. Consolidated where reported.

Source: Mankind Pharma’s results filed with NSE, consolidated (the whole group). Net profit is the share of Mankind Pharma’s own shareholders where the filing separates it. Profit vs year ago compares with the same quarter a year earlier; – where that quarter is not on file or made a loss.

Download results (zip) A spreadsheet of the quarterly results and balance sheets, with the original filings from NSE.

Source: Mankind Pharma’s half-yearly statements of assets and liabilities filed with NSE, consolidated. Companies file these every September and March.

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, urology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory, and other diseases. It also provides consumer healthcare products, such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural and pet food products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Telmikind-Am, Gudcef, Glimestar-M, Candi Force, Nurokind-Gold, Telmikind-H, Telmikind, Nurokind-Lc, Nurokind Plus-Rf, Vomikind, Cefakind, Glizid-M, Monticope, and Gudcef-Cv brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Industry

Drug Manufacturers - Specialty & Generic

Based in

New Delhi

Employees

20,451

Company website · Profile: Yahoo Finance

No headlines name Mankind Pharma in the last day or two.

• Interim Dividend - Re 1 Per Share

  Dividend · ex-date 8 August 2025

Source: NSE. Latest first.